Acadia Pharma Appoints New CMO, Elects Director
Ticker: ACAD · Form: 8-K · Filed: 2024-05-29T00:00:00.000Z
Sentiment: neutral
Topics: executive-appointment, board-election, corporate-governance
Related Tickers: ACAD
TL;DR
Acadia Pharma brings in a new CMO and adds a director to the board.
AI Summary
Acadia Pharmaceuticals Inc. announced on May 29, 2024, the appointment of Dr. Anya Schiess as Chief Medical Officer and the election of Dr. David E. Michelson to its Board of Directors. The company also reported on the outcome of its 2024 Annual Meeting of Stockholders, where all director nominees were elected and a proposal to ratify the appointment of its independent registered public accounting firm was approved.
Why It Matters
These executive and board changes could signal shifts in the company's strategic direction and leadership, potentially impacting its drug development and commercialization efforts.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance matters such as director elections and executive appointments, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Acadia Pharmaceuticals Inc. (company) — Registrant
- Dr. Anya Schiess (person) — Appointed Chief Medical Officer
- Dr. David E. Michelson (person) — Elected to Board of Directors
- May 29, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Anya Schiess has been appointed as the new Chief Medical Officer.
Who was elected to the Board of Directors?
Dr. David E. Michelson was elected to the Board of Directors.
What was the outcome of the 2024 Annual Meeting of Stockholders regarding director nominees?
All director nominees were elected at the 2024 Annual Meeting of Stockholders.
Was the appointment of the independent registered public accounting firm ratified?
Yes, the proposal to ratify the appointment of the independent registered public accounting firm was approved.
What is Acadia Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 12830 El Camino Real, Suite 400, San Diego, California, 92130.
Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-05-29 17:23:31
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- d27582d8k.htm (8-K) — 41KB
- 0001193125-24-149336.txt ( ) — 162KB
- acad-20240529.xsd (EX-101.SCH) — 3KB
- acad-20240529_lab.xml (EX-101.LAB) — 18KB
- acad-20240529_pre.xml (EX-101.PRE) — 11KB
- d27582d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Acadia Pharmaceuticals Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to Registration Statement No. 333-279784). 104 Cover page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acadia Pharmaceuticals Inc. Date: May 29, 2024 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer & Secretary